Business Context and Reporting Period
Krystal Biotech, Inc. (KRYS) is a commercial-stage biotechnology company focused on genetic medicines. The company's primary commercial product is VYJUVEK (beremagene geperpavec-svdt), the first FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa (DEB). This filing covers the quarterly period ended June 30, 2024.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 |
|---|---|---|
| Product Revenue, Net | $70.3 million | $115.5 million |
| Cost of Goods Sold | $6.0 million | $8.4 million |
| Gross Margin | 91% | 93% |
| Net Income (Loss) | $15.6 million | $16.5 million |
| Diluted EPS | $0.53 | $0.56 |
| Cash and Cash Equivalents | $345.8 million | $345.8 million (as of June 30) |
| Total Investments (Short & Long-term) | $283.1 million | $283.1 million (as of June 30) |
| Total Liquidity | $559.6 million | $559.6 million (as of June 30) |
| Operating Cash Flow | N/A | $11.7 million |
Material Changes vs. Prior Period
- Revenue Growth: The company reported $70.3 million in revenue for Q2 2024 compared to zero in Q2 2023, driven by the commercial launch of VYJUVEK following FDA approval in May 2023. Cumulative net product revenue since launch reached $166.2 million.
- Profitability: The company achieved net income of $15.6 million in Q2 2024, a significant turnaround from a net loss of $33.2 million in the same period in 2023. This shift was driven by revenue recognition and interest income, partially offset by increased operating expenses.
- Operating Expenses: Total operating expenses increased to $61.7 million in Q2 2024 from $38.0 million in Q2 2023. This increase includes a $12.5 million litigation settlement expense related to a milestone payment to PeriphaGen, Inc., triggered by reaching $100 million in cumulative sales.
- Interest Income: Interest and other income, net, rose to $7.5 million in Q2 2024 from $4.8 million in Q2 2023, reflecting higher interest rates and increased investment balances.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes cash, cash equivalents, and short-term investments of approximately $559.6 million are sufficient to fund operations for at least the next 12 months.
- Regulatory Milestones: The company expects an EMA decision on its Marketing Authorization Application (MAA) for B-VEC in the second half of 2024. A Japan New Drug Application is anticipated in the second half of 2024, with potential authorization in 2025.
- Pipeline Progress:
- Respiratory: Phase 1 studies for KB407 (Cystic Fibrosis) and KB408 (Alpha-1 Antitrypsin Deficiency) are ongoing.
- Ophthalmology: A registrational study for ophthalmic B-VEC is planned for initiation in Q4 2024.
- Oncology: Phase 1 studies for KB707 (intratumoral and inhaled) are ongoing, with interim data expected in Q4 2024.
- Contingent Liabilities: The company has accrued $25.0 million for litigation settlements related to PeriphaGen. Two additional contingent milestone payments of $12.5 million each remain payable upon reaching $200 million and $300 million in cumulative sales.
- Key Risks: Risks include dependence on the commercial success of VYJUVEK, potential manufacturing scale-up challenges, regulatory approval delays for international markets, and the need for additional capital if revenue growth does not meet expectations.
Investor Verification Checklist
- Cumulative Sales Milestones: Verify the timing of the next $12.5 million contingent payment to PeriphaGen, which is triggered by reaching $200 million in cumulative sales.
- Manufacturing Capacity: Confirm the status of the technical transfer of VYJUVEK manufacturing from the ANCORIS facility to the new ASTRA facility to ensure supply meets demand.
- Reimbursement Rates: Monitor the 97% positive access determination rate for commercial and Medicaid plans and any changes in reimbursement policies that could impact net revenue.
- International Approvals: Track the EMA decision timeline in H2 2024 and the PMDA filing status in Japan, as these are critical for future revenue growth.
- Stock-Based Compensation: Review the $22.5 million in stock-based compensation expense for the six months ended June 30, 2024, and its impact on future cash burn and dilution.